
Genzyme, a Sanofi company , reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints.
Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab (Lemtrada(TM)) as compared with Rebif(R) (44 mcg subcutaneous interferon beta-1a).
Results for both of these co-primary endpoints were highly statistically significant. CARE-MS II is the randomized Phase III clinical trial comparing the investigational drug alemtuzumab to interferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS). Patients were required to have experienced a relapse while on a prior therapy to be eligible for CARE-MS II. Genzyme is developing alemtuzumab in MS in collaboration with Bayer HealthCare.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307